Home » Stocks » Myovant Sciences

Myovant Sciences Ltd. (MYOV)

Stock Price: $15.24 USD -0.58 (-3.67%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.37B
Revenue (ttm) 33.33M
Net Income (ttm) -253.95M
Shares Out 90.15M
EPS (ttm) -2.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $15.24
Previous Close $15.82
Change ($) -0.58
Change (%) -3.67%
Day's Open 15.70
Day's Range 15.01 - 15.96
Day's Volume 468,571
52-Week Range 4.14 - 23.04

More Stats

Market Cap 1.37B
Enterprise Value 1.48B
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 90.15M
Float 31.79M
EPS (basic) -2.85
EPS (diluted) -2.85
FCF / Share -2.44
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.00M
Short Ratio 1.26
Short % of Float 6.30%
Beta 2.59
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 41.22
PB Ratio 70.01
Revenue 33.33M
Operating Income -243.30M
Net Income -253.95M
Free Cash Flow -217.46M
Net Cash -106.16M
Net Cash / Share -1.18
Gross Margin 100.00%
Operating Margin -729.90%
Profit Margin -761.80%
FCF Margin -652.37%
ROA -76.58%
ROE -622.01%
ROIC -197.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 6
Overweight 1
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(102.49% upside)
Current: $15.24
Target: 30.86
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-275-265-141-55.86
Net Income-289-274-143-83.44
Shares Outstanding85.8466.9159.5249.18
Earnings Per Share-3.37-4.09-2.41-1.70
Operating Cash Flow-221-224-117-18.22
Capital Expenditures-1.10-1.24-0.60-0.97
Free Cash Flow-222-225-118-19.18
Cash & Equivalents79.64156109181
Total Debt12699.3843.62-
Net Cash / Debt-46.5756.6965.00181
Book Value-1084.3337.73167
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Myovant Sciences Ltd.
Country United Kingdom
Employees 214
CEO Lynn Seely

Stock Information

Ticker Symbol MYOV
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSE: MYOV
IPO Date October 27, 2016


Myovant Sciences, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. As of December 27, 2019, Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.